Expertise in
4
conditions

Dr. Jun Zhang

Physiatry
Jamaica Hospital Medical Center
8900 Van Wyck Expy, 
Jamaica, NY 
Expertise in
4
conditions
Jamaica Hospital Medical Center
8900 Van Wyck Expy, 
Jamaica, NY 

Overview

Jun Zhang is a Physiatrist in Jamaica, New York. Dr. Zhang is highly rated in 4 conditions, according to our data. His top areas of expertise are Stroke, Subdural Hematoma, Chronic Subdural Hematoma, and Subarachnoid Hemorrhage.

His clinical research consists of co-authoring 22 peer reviewed articles and participating in 12 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Physiatry

Licenses

Physical Medicine & Rehabilitation in NY

Hospital Affiliations

Jamaica Hospital Medical Center

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Health First
  • HMO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
MetroPlus Health
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE-MEDICAID PLAN
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 3 Less Insurance Carriers -

Locations

Jamaica Hospital Medical Center
8900 Van Wyck Expy, Jamaica, NY 11418
Other Locations
St. Charles Hospital
200 Belle Terre Rd, Port Jefferson, NY 11777

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab
Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab
Enrollment Status: Active_not_recruiting
Publish Date: December 03, 2025
Intervention Type: Other, Drug, Radiation, Procedure
Study Drugs: Atezolizumab, Carboplatin, Cisplatin, Etoposide
Study Phase: Phase 3
Randomized Phase II Trial of Topotecan Plus M6620 (VX-970, Berzosertib) Vs. Topotecan Alone in Patients With Relapsed Small-Cell Lung Cancer
Randomized Phase II Trial of Topotecan Plus M6620 (VX-970, Berzosertib) Vs. Topotecan Alone in Patients With Relapsed Small-Cell Lung Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 19, 2025
Intervention Type: Procedure, Drug
Study Drugs: Berzosertib, Topotecan Hydrochloride
Study Phase: Phase 2
A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study)
A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study)
Enrollment Status: Active_not_recruiting
Publish Date: May 21, 2025
Intervention Type: Other, Biological
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 3
A Phase IB and Randomized Open-Label Phase II Study of Berzosertib (M6620, VX-970) in Combination With Carboplatin/Gemcitabine/Pembrolizumab in Patients With Chemotherapy-Naïve Advanced Non-Small Cell Lung Cancer of Squamous Cell Histology
A Phase IB and Randomized Open-Label Phase II Study of Berzosertib (M6620, VX-970) in Combination With Carboplatin/Gemcitabine/Pembrolizumab in Patients With Chemotherapy-Naïve Advanced Non-Small Cell Lung Cancer of Squamous Cell Histology
Enrollment Status: Active_not_recruiting
Publish Date: July 03, 2024
Intervention Type: Procedure, Drug, Biological
Study Drugs: Berzosertib, Carboplatin, Gemcitabine Hydrochloride, Pembrolizumab
Study Phase: Phase 1/Phase 2
A Randomized, Open-label, Phase II Study of Canakinumab or Pembrolizumab as Monotherapy or in Combination as Neoadjuvant Therapy in Subjects With Resectable Non-small Cell Lung Cancer (CANOPY-N)
A Randomized, Open-label, Phase II Study of Canakinumab or Pembrolizumab as Monotherapy or in Combination as Neoadjuvant Therapy in Subjects With Resectable Non-small Cell Lung Cancer (CANOPY-N)
Enrollment Status: Terminated
Publish Date: June 20, 2024
Intervention Type: Drug
Study Drugs: Canakinumab, Pembrolizumab
Study Phase: Phase 2
A Multi-center Phase II Study of Ipatasertib in Combination With Docetaxel in Metastatic/Advanced NSCLC Patients Who Have Failed or Are Intolerant to 1st Line Immunotherapy (Ipat-Lung)
A Multi-center Phase II Study of Ipatasertib in Combination With Docetaxel in Metastatic/Advanced NSCLC Patients Who Have Failed or Are Intolerant to 1st Line Immunotherapy (Ipat-Lung)
Enrollment Status: Unknown
Publish Date: November 07, 2023
Intervention Type: Drug
Study Drug: Ipatasertib
Study Phase: Phase 2
Use Peripheral Blood Proteomics to Predict the Treatment Response and Toxicities in NSCLC Immunotherapy
Use Peripheral Blood Proteomics to Predict the Treatment Response and Toxicities in NSCLC Immunotherapy
Enrollment Status: Terminated
Publish Date: October 12, 2023
Intervention Type: Procedure
A Phase II Study of MEDI4736 (Durvalumab) Plus Tremelimumab as Therapy for Patients With Previously Treated Anti-PD-1/PD-L1 Resistant Stage IV Squamous Cell Lung Cancer (Lung-Map Non-Match Sub-Study)
A Phase II Study of MEDI4736 (Durvalumab) Plus Tremelimumab as Therapy for Patients With Previously Treated Anti-PD-1/PD-L1 Resistant Stage IV Squamous Cell Lung Cancer (Lung-Map Non-Match Sub-Study)
Enrollment Status: Completed
Publish Date: June 09, 2023
Intervention Type: Biological, Other
Study Drugs: Durvalumab, Tremelimumab
Study Phase: Phase 2
A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)
A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)
Enrollment Status: Completed
Publish Date: June 01, 2023
Intervention Type: Biological, Drug, Other
A Phase II Study of Carboplatin Plus Pemetrexed Plus Atezolizumab Plus Bevacizumab in Chemotherapy and Immunotherapy-naïve Patients With Stage IV Non-squamous Non-small Cell Lung Cancer: Big Ten Cancer Research Consortium BTCRC-LUN17-139
A Phase II Study of Carboplatin Plus Pemetrexed Plus Atezolizumab Plus Bevacizumab in Chemotherapy and Immunotherapy-naïve Patients With Stage IV Non-squamous Non-small Cell Lung Cancer: Big Ten Cancer Research Consortium BTCRC-LUN17-139
Enrollment Status: Terminated
Publish Date: March 01, 2023
Intervention Type: Drug
Study Drugs: Carboplatin, Pemetrexed, Atezolizumab, Bevacizumab
Study Phase: Phase 2
The Role of Microbiome in Lung Cancer and Other Malignancies
The Role of Microbiome in Lung Cancer and Other Malignancies
Enrollment Status: Completed
Publish Date: May 11, 2022
Intervention Type: Procedure, Other, Genetic
A Phase II Study of Talazoparib (BMN 673) in Patients With Homologous Recombination Repair Deficiency Positive Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
A Phase II Study of Talazoparib (BMN 673) in Patients With Homologous Recombination Repair Deficiency Positive Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
Enrollment Status: Completed
Publish Date: June 23, 2021
Intervention Type: Other, Drug
Study Drug: Talazoparib
Study Phase: Phase 2
View 11 Less Clinical Trials

22 Total Publications

Author Correction: Exome analysis links kidney malformations to developmental disorders and reveals causal genes.
Author Correction: Exome analysis links kidney malformations to developmental disorders and reveals causal genes.
Journal: Nature communications
Published: October 09, 2025
Similar Doctors
Expertise in
8
conditions
Dr. Joseph Feinberg
Physiatry
Expertise in
8
conditions
Dr. Joseph Feinberg
Physiatry

HSS 75TH Street Campus

429 E 75th St Fl 3, 
New York, NY 
 (8.8 miles away)
646-838-0645
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Joseph Feinberg is a Physiatrist in New York, New York. Dr. Feinberg is highly rated in 8 conditions, according to our data. His top areas of expertise are Hereditary Neuralgic Amyotrophy, Brachial Plexopathy, Axillary Nerve Dysfunction, and Thoracic Outlet Syndrome. Dr. Feinberg is currently accepting new patients.

Expertise in
2
conditions
Dr. Wayne Gordon
Physiatry
Expertise in
2
conditions
Dr. Wayne Gordon
Physiatry

Office

5 E 98th St # 1240B, 
New York, NY 
 (9.2 miles away)
212-659-9363
Languages Spoken:
English

Wayne Gordon is a Physiatrist in New York, New York. Dr. Gordon is highly rated in 2 conditions, according to our data. His top areas of expertise are Traumatic Brain Injury and Concussion.

Expertise in
4
conditions
Dr. Kathleen D. Francis
Physiatry
Expertise in
4
conditions
Dr. Kathleen D. Francis
Physiatry
200 South Orange Ave, 
Livingston, NJ 
 (28.7 miles away)
973-322-7366
Languages Spoken:
English
See accepted insurances

Kathleen Francis is a Physiatrist in Livingston, New Jersey. Dr. Francis is highly rated in 4 conditions, according to our data. Her top areas of expertise are Lymphedema, Primary Intestinal Lymphangiectasia, Meige Disease, and Lymphangiectasis.

Frequently Asked Questions about Dr. Jun Zhang

How do I make an appointment with Dr. Jun Zhang?

You can book an appointment with Dr. Jun Zhang by calling their office at 718-206-6894. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Jun Zhang a top-rated expert for Stroke?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Jun Zhang is classified as an Advanced expert for Stroke, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Jun Zhang specialize in?

While Dr. Jun Zhang is a Physiatry, they have specific expertise in Stroke, Subdural Hematoma, and Chronic Subdural Hematoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Physiatry.

Does Dr. Jun Zhang participate in research or clinical trials?

Yes. Dr. Jun Zhang has published 22 articles and abstracts on conditions like Stroke. You can view a list of Dr. Jun Zhang's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Jun Zhang accept my insurance?

Dr. Jun Zhang accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 718-206-6894 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Zhang's expertise for a condition
ConditionClose
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile